Stocks Health care CRNX
NASDAQ · Health careCrinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. brought in $42.2M of revenue over the twelve months to June 30, 2026, up 2,928.4% from a year earlier. It posted a net loss of $501.6M. In fiscal 2025 capital spending exceeded operating cash flow by $383.7M. At June 30, 2026 it held $55.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
Key facts about Crinetics Pharmaceuticals, Inc.
- Net worth
- Crinetics Pharmaceuticals, Inc. has a market value (market cap) of $9B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $7.7M (+640.7% year on year), with a net loss of $465.3M. Over the 12 months to June 30, 2026: revenue $42.2M, net loss $501.6M.
- Cash flow
- In fiscal 2025 operations used $377.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 3, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Crinetics Pharmaceuticals, Inc.'s next report was expected around October 12, 2026 and is not on file with the SEC yet.
What Crinetics Pharmaceuticals, Inc. does
Crinetics Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRNX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.7M | -$465.3M | -$4.95 | -$383.7M |
| 2024 | $1M | -$298.4M | -$3.69 | -$234M |
| 2023 | $4M | -$214.5M | -$3.69 | -$173.3M |
| 2022 | $4.7M | -$163.9M | -$3.15 | -$116.9M |
| 2021 | $1.1M | -$107.6M | -$2.80 | -$89M |
| 2020 | $71K | -$73.8M | -$2.42 | -$62.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CRNX ranks in Health care
Latest SEC filings
What Crinetics Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026Deregistration 15-12G
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
Insider trades
What the people running Crinetics Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 33 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other change | 248,043 | $21.1M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 1,000 | $85K |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 136,805 | $11.6M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 106,000 | $9M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 110,000 | $9.4M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 100,000 | $8.5M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 111,100 | $9.4M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 111,100 | $9.4M |
Who owns CRNX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Dapice Joshua J.13G, passive with 30 related filers | 8.5% | February 5, 2026 |
| Farallon Capital Management, L.L.C.13G, passive with 28 related filers | 8.5% | August 3, 2026 |
| Wellington Management Group LLP13G, passive with 3 related filers | 6.8% | August 13, 2026 |
| Driehaus Capital Management LLC13G, passive | 6.11% | May 15, 2026 |
| Vanguard Capital Management13G, passive | 5.19% | April 29, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 5.1% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 266 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 15,840,219 | +80,420 |
| BlackRock, Inc. | 9,758,938 | +1,280,123 |
| Farallon Capital Management, L.L.C. | 8,989,098 | +651,000 |
| Wellington Management Group Llp | 7,131,084 | -1,026,120 |
| Driehaus Capital Management LLC | 6,463,551 | +67,629 |
| Vanguard Portfolio Management LLC | 4,832,614 | +194,103 |
| Vanguard Capital Management LLC | 4,745,262 | +71,327 |
| Jupiter Topco LLC | 4,557,689 | new |
| Geode Capital Management, LLC | 2,727,633 | +246,870 |
| State Street Corp | 2,689,350 | +286,304 |
| Bellevue Group AG | 2,620,000 | -660,000 |
| Baker Bros. Advisors LP | 2,351,465 | 0 |
| Polar Capital Holdings Plc | 2,274,411 | new |
| Pictet Asset Management Holding SA | 2,075,375 | +191,094 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,678,490 | -37,955 |
| Siren, L.L.C. | 1,420,788 | -482,848 |
| First Light Asset Management, LLC | 1,360,866 | +271,196 |
| Jpmorgan Chase & Co | 1,365,030 | +40,362 |
| Morgan Stanley | 1,338,531 | +418,845 |
| Bank of America Corp | 1,333,071 | +616,946 |
Insiders
2 insiders reported holding 172,126 shares in total, about $14.6M at the last price.
| Holder | Shares |
|---|---|
| Knight Jeff E.Chief Dev. & Operating Officer | 105,289 |
| Pizzuti DanaChief Med and Dev Officer | 66,837 |
Questions about CRNX
What does Crinetics Pharmaceuticals, Inc. do?
Crinetics Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as CRNX. Its shares trade on NASDAQ under the ticker CRNX.
What is Crinetics Pharmaceuticals, Inc.'s net worth?
Crinetics Pharmaceuticals, Inc. has a market value (market cap) of $9B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Crinetics Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $501.6M on revenue of $42.2M.
How much revenue does Crinetics Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Crinetics Pharmaceuticals, Inc. reported revenue of $42.2M. That is 2,928.4% more than a year earlier.
When did Crinetics Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the deregistration from September 11, 2026.
When is Crinetics Pharmaceuticals, Inc.'s next earnings report?
Crinetics Pharmaceuticals, Inc.'s next report was expected around October 12, 2026 and is not on file with the SEC yet.
Similar companies
Compare CRNX with
Follow CRNX
Get an email when Crinetics Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Crinetics Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.